Key result
Rosuvastatin treatment significantly decreased mean platelet volume from 8.4 fl to 8.1 fl (p < 0.001) in patients with uncontrolled primary dyslipidemia.
Why the study?
Does rosuvastatin reduce mean platelet volume in patients with uncontrolled primary dyslipidemia?
Population
60 subjects total: 30 patients with uncontrolled primary dyslipidemia on hypolipidemic diet treatment, and…
Comparison
Rosuvastatin 10 mg/day for 12 weeks vs Baseline values and normolipidemic healthy…
Design
Cohort
Follow-up
12 weeks
Authors
Loading...
May support pleiotropic antiplatelet effects of rosuvastatin; leaves open whether this improves outcomes in dyslipidemia.
Does rosuvastatin reduce mean platelet volume in patients with uncontrolled primary dyslipidemia?
Absolute Event Rate: 8.1% vs 8.4%
p-value: p=< 0.001
Rosuvastatin 10 mg/day significantly reduces mean platelet volume in patients with primary dyslipidemia, suggesting an anti-platelet effect independent of its lipid-lowering properties.
Çoban et al. (2008) studied Uncontrolled primary dyslipidemia (n=60). Rosuvastatin vs. Baseline (pre-treatment) was evaluated on Mean platelet volume (MPV) (p=< 0.001). Rosuvastatin treatment significantly decreased mean platelet volume from 8.4 fl to 8.1 fl (p < 0.001) in patients with uncontrolled primary dyslipidemia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: